January 15, 2022
Dermavant Presents New Patient Satisfaction Data f ...
Read More
January 7, 2022
Dermavant to Present New Data from Phase 3 PSOARIN ...
Read More
December 9, 2021
Dermavant Announces Publication of PSOARING 1 ...
Read More
December 9, 2021
The New England Journal of Medicine: Phase 3 Trial ...
Read More
September 30, 2021
Dermavant Showcases New Long-Term Data from Phase ...
Read More
September 23, 2021
Dermavant to Present New Data on Phase 3 PSOARING ...
Read More
September 9, 2021
Dermavant Announces First Patient Dosed in ADORING ...
Read More
August 10, 2021
Dermavant Announces FDA Acceptance for Filing of N ...
Read More
June 7, 2021
Dermavant Announces $200 Million of Financing ...
Read More
June 3, 2021
Dermavant Submits New Drug Application (NDA) to FD ...
Read More
May 6, 2021
Dermavant Announces Appointment of Michael Swartzb ...
Read More
April 16, 2021
Dermavant Announces Tapinarof Data Presentations a ...
Read More
March 25, 2021
FORTUNE Names Dermavant One of the 2021 Best Workp ...
Read More
March 11, 2021
Dermavant Announces Tapinarof Data Presentation at ...
Read More
February 18, 2021
Positive Data from PSOARING 3 Support Long-Term Us ...
Read More
January 21, 2021
Dermavant Announces Tapinarof Data Presentation at ...
Read More
November 17, 2020
Dermavant Named One of Fortune® Magazine’s 2020 ...
Read More
October 27, 2020
Dermavant’s Pivotal Phase 3 PSOARING Data for Ta ...
Read More
October 22, 2020
Dermavant Announces Presentation of Tapinarof Pivo ...
Read More
August 26, 2020
Dermavant Reports Positive Phase 3 Results for Tap ...
Read More
